Chris Malone Mendez
After years of criminalization and marginalization, scientists have begun looking at LSD’s medical benefits more closely, so much so that the Food and Drug Administration just issued a groundbreaking stamp of approval.
Biopharmaceutical company Mind Medicine announced March 7 that the FDA has awarded “breakthrough therapy” status to its trial of patients using MM120 (lysergide D-tartrate) to treat anxiety. MindMed chief medical officer Daniel Karlin explained what the trial approval means going forward. “A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need with morbidity and mortality associated with it,” he told CNN. The move allows the FDA to “engage more closely in drug development” and speeds up the road to final approval as the agency is involved throughout the process.
MM120 is the codename for MindMed’s lysergide D-tartrate compound, which resembles and delivers similar effects to lysergic acid diethylamide, known more commonly as LSD. In its ongoing trial, which kicked off in 2022, MindMed has so far found that a single dose of MM120 led to a 48-percent rate of remission from generalized anxiety disorder after 12 weeks following the drug’s administration. Scientists also noted significantly improved clinical signs of generalized anxiety disorder among 65 percent of patients within three months.
“The clinical improvement for many patients was more than double what we see with today’s standard of care,” Karlin said. “This occurred at all levels of anxiety, from moderate all the way up to severe.”
[…]
Via https://www.mensjournal.com/news/dose-lsd-treat-anxiety-study
Click this link for the original source of this article.
Author: stuartbramhall
This content is courtesy of, and owned and copyrighted by, https://stuartbramhall.wordpress.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.